These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies. Ensinck MM; Carlon MS Cells; 2022 Jun; 11(12):. PubMed ID: 35740997 [TBL] [Abstract][Full Text] [Related]
6. The Impact of Highly Effective Cystic Fibrosis Transmembrane Conductance Regulator Modulators on the Health of Female Subjects With Cystic Fibrosis. Taylor-Cousar JL; Shteinberg M; Cohen-Cymberknoh M; Jain R Clin Ther; 2023 Mar; 45(3):278-289. PubMed ID: 36841738 [TBL] [Abstract][Full Text] [Related]
7. A Proteomic Survey of the Cystic Fibrosis Transmembrane Conductance Regulator Surfaceome. Iazzi M; Sadeghi S; Gupta GD Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511222 [TBL] [Abstract][Full Text] [Related]
8. The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis. Sergeev V; Chou FY; Lam GY; Hamilton CM; Wilcox PG; Quon BS Ann Am Thorac Soc; 2020 Feb; 17(2):147-154. PubMed ID: 31661636 [TBL] [Abstract][Full Text] [Related]
9. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist. Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995 [TBL] [Abstract][Full Text] [Related]
10. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations. Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449 [TBL] [Abstract][Full Text] [Related]
11. Activation of 3-phosphoinositide-dependent kinase 1 (PDK1) and serum- and glucocorticoid-induced protein kinase 1 (SGK1) by short-chain sphingolipid C4-ceramide rescues the trafficking defect of ΔF508-cystic fibrosis transmembrane conductance regulator (ΔF508-CFTR). Caohuy H; Yang Q; Eudy Y; Ha TA; Xu AE; Glover M; Frizzell RA; Jozwik C; Pollard HB J Biol Chem; 2014 Dec; 289(52):35953-68. PubMed ID: 25384981 [TBL] [Abstract][Full Text] [Related]
12. Where Is the Cystic Fibrosis Transmembrane Conductance Regulator? Barbry P; Marcet B; Caballero I Am J Respir Crit Care Med; 2021 May; 203(10):1214-1216. PubMed ID: 33428551 [No Abstract] [Full Text] [Related]
13. Binding screen for cystic fibrosis transmembrane conductance regulator correctors finds new chemical matter and yields insights into cystic fibrosis therapeutic strategy. Hall JD; Wang H; Byrnes LJ; Shanker S; Wang K; Efremov IV; Chong PA; Forman-Kay JD; Aulabaugh AE Protein Sci; 2016 Feb; 25(2):360-73. PubMed ID: 26444971 [TBL] [Abstract][Full Text] [Related]
14. Progress towards next-generation therapeutics for cystic fibrosis. O'Neil DA; Fraser-Pitt D Future Med Chem; 2014 Jun; 6(9):1067-79. PubMed ID: 25068988 [TBL] [Abstract][Full Text] [Related]
15. Prenatal Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Promising Way to Change the Impact of Cystic Fibrosis. Gómez-Montes E; Salcedo Lobato E; Galindo Izquierdo A; García Alcázar D; Villalain González C; Moral-Pumarega MT; Bustos Lozano G; Luna-Paredes C Fetal Diagn Ther; 2023; 50(2):136-142. PubMed ID: 36996799 [TBL] [Abstract][Full Text] [Related]
16. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Pettit RS Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718 [TBL] [Abstract][Full Text] [Related]
17. Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis: progress to date. Becq F Drugs; 2010 Feb; 70(3):241-59. PubMed ID: 20166764 [TBL] [Abstract][Full Text] [Related]
18. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Kuk K; Taylor-Cousar JL Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827 [TBL] [Abstract][Full Text] [Related]
19. The Intestinal Microbiome and Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Emerging Themes in the Management of Gastrointestinal Manifestations of Cystic Fibrosis. Karb DB; Cummings LC Curr Gastroenterol Rep; 2021 Aug; 23(10):17. PubMed ID: 34448955 [TBL] [Abstract][Full Text] [Related]
20. The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation. Caverly LJ; Riquelme SA; Hisert KB Clin Chest Med; 2022 Dec; 43(4):647-665. PubMed ID: 36344072 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]